Search

Your search keyword '"Pinilla-Ibarz, Javier"' showing total 5 results
Start Over Author "Pinilla-Ibarz, Javier" Publisher biomed central
5 results on '"Pinilla-Ibarz, Javier"'

2. Correction: Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Author

Januzzi, James L., Garasic, Joseph M., Kasner, Scott E., McDonald, Vickie, Petrie, Mark C., Seltzer, Jonathan, Mauro, Michael, Croce, Kevin, Berman, Ellin, Deininger, Michael, Hochhaus, Andreas, Pinilla-Ibarz, Javier, Nicolini, Franck, Kim, Dong-Wook, DeAngelo, Daniel J., Kantarjian, Hagop, Xu, Jing, Hall, Tracey, Srivastava, Shouryadeep, Naranjo, Daniel, and Cortes, Jorge

Published
2022
Full Text
View/download PDF

3. Retrospective analysis of arterial occlusive events in the PACE trial by an independent adjudication committee

Author

Januzzi, James L., Garasic, Joseph M., Kasner, Scott E., McDonald, Vickie, Petrie, Mark C., Seltzer, Jonathan, Mauro, Michael, Croce, Kevin, Berman, Ellin, Deininger, Michael, Hochhaus, Andreas, Pinilla-Ibarz, Javier, Nicolini, Franck, Kim, Dong-Wook, DeAngelo, Daniel J., Kantarjian, Hagop, Xu, Jing, Hall, Tracey, Srivastava, Shouryadeep, Naranjo, Daniel, and Cortes, Jorge

Published
2022
Full Text
View/download PDF

4. Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia

Author

Atallah, Ehab, Schiffer, Charles A., Weinfurt, Kevin P., Zhang, Mei-Jie, Radich, Jerald P., Oehler, Vivian G., Pinilla-Ibarz, Javier, Deininger, Michael W. N., Lin, Li, Larson, Richard A., Mauro, Michael J., Moore, Joseph O., Ritchie, Ellen K., Shah, Neil P., Silver, Richard T., Wadleigh, Martha, Cortes, Jorge, Thompson, James, Guhl, Jessica, Horowitz, Mary M., and Flynn, Kathryn E.

Published
2018
Full Text
View/download PDF

5. Biomarkers for determining the prognosis in chronic myelogenous leukemia.

Author

Sweet, Kendra, Ling Zhang, and Pinilla-Ibarz, Javier

Subjects
BIOMARKERS, MYELOID leukemia, LIFE expectancy, IMATINIB, GENE expression, GENETIC regulation
Abstract

The introduction of BCR-ABL1 tyrosine kinase inhibitors (TKIs) for treatment of chronic myelogenous leukemia in chronic phase (CML-CP) has revolutionized therapy, altering the outcome from one of shortened life expectancy to long-term survival. With over 10 years of long-term treatment with imatinib and several years of experience with the next generation of TKIs, including nilotinib, dasatinib, bosutinib, and ponatinib, it is becoming clear that many clinical parameters have great impact on the prognosis of patients with CML. Emerging novel gene expression profiling and molecular techniques also provide new insights into CML pathogenesis and have identified potential prognostic markers and therapeutic targets. This review presents the supporting data and discusses how certain clinical characteristics at diagnosis, the depth of early response, the presence of certain kinase domain mutations, and additional molecular changes serve as prognostic factors that may guide individualized treatment decisions for patients with CML-CP. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results